Jules Jacob

Jules Jacob has 30 years of drug development experience and was previously Senior Director, Product Development at Aprecia Pharmaceuticals where he headed the development of Spritam®, the first FDA-approved dosage form manufactured using 3-Dimensional Printing and other 505(b)(2) pipeline products. Prior to that Mr. Jacob was Director of Formulation Development at Panacos Pharmaceuticals, developing first-in-class maturation inhibitors for the treatment of HIV, and Director of Research and Development and Director of Technology Development at Spherics Pharmaceuticals developing bioadhesive dosage forms for the treatment of CNS disorders, following the 505 (b)(2) regulatory pathway.

Mr. Jacob holds over 30 issued patents (the US and international) and 38 US patent applications in the fields of drug delivery (proteins, peptides, DNA), nanoencapsulation, microencapsulation, solid oral dosage formulation, polymer compositions, gene therapy, tumor immunotherapy, protein micronization and formulation, imaging and bioadhesion. He has authored more than 30 scientific articles and book chapters and was a Grand Award winner of the 2005 Eurand-CRS sponsored “Novel Approaches in Industrial Oral Drug Delivery Award”. Mr. Jacob completed his undergraduate degree and graduate education in biological and medical sciences at Brown University and has an active visiting faculty appointment in the Department of Molecular Pharmacology, Physiology, and Biotechnology at Brown.